Benign SARS-CoV-2 infection in MOG-antibodies associated disorder during tocilizumab treatment

Mult Scler Relat Disord. 2020 Nov:46:102592. doi: 10.1016/j.msard.2020.102592. Epub 2020 Oct 21.

Abstract

Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD) represents a demyelinating disorder for which tocilizumab, an anti-IL6 receptor, has been tested to prevent disabling relapses. In a subgroup of patients affected with novel Coronavirus disease (COVID-19), tocilizumab has also increased the survival rate. We present the case of a 31-years-old Caucasian patient who experienced an almost asymptomatic Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection during treatment with tocilizumab, which was continued due to the very high risk of relapses of the patient. According to this case, tocilizumab might be not discontinued during COVID-19.

Keywords: Anti-IL6 receptor; COVID-19; MOGAD; Monoclonal antibody; SARS-CoV-2; Tocilizumab.

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Antibodies, Monoclonal, Humanized / therapeutic use*
  • COVID-19 Drug Treatment*
  • Coronavirus Infections / drug therapy*
  • Coronavirus Infections / epidemiology
  • Coronavirus Infections / virology
  • Female
  • Humans
  • Pneumonia, Viral / drug therapy
  • SARS-CoV-2 / drug effects
  • SARS-CoV-2 / pathogenicity*
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • tocilizumab